Molecular-Based Treatment Strategies for Osteoporosis: a Literature Review

Total Page:16

File Type:pdf, Size:1020Kb

Molecular-Based Treatment Strategies for Osteoporosis: a Literature Review International Journal of Molecular Sciences Review Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review Yuichiro Ukon , Takahiro Makino , Joe Kodama, Hiroyuki Tsukazaki, Daisuke Tateiwa, Hideki Yoshikawa and Takashi Kaito * Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan; [email protected] (Y.U.); [email protected] (T.M.); [email protected] (J.K.); [email protected] (H.T.); [email protected] (D.T.); [email protected] (H.Y.) * Correspondence: [email protected]; Tel.: +81-6-6879-3552 Received: 25 April 2019; Accepted: 22 May 2019; Published: 24 May 2019 Abstract: Osteoporosis is an unavoidable public health problem in an aging or aged society. Anti-resorptive agents (calcitonin, estrogen, and selective estrogen-receptor modulators, bisphosphonates, anti-receptor activator of nuclear factor κB ligand antibody along with calcium and vitamin D supplementations) and anabolic agents (parathyroid hormone and related peptide analogs, sclerostin inhibitors) have major roles in current treatment regimens and are used alone or in combination based on the pathological condition. Recent advancements in the molecular understanding of bone metabolism and in bioengineering will open the door to future treatment paradigms for osteoporosis, including antibody agents, stem cells, and gene therapies. This review provides an overview of the molecular mechanisms, clinical evidence, and potential adverse effects of drugs that are currently used or under development for the treatment of osteoporosis to aid clinicians in deciding how to select the best treatment option. Keywords: osteoporosis; bone metabolism; osteoblast; osteoclast; bisphosphonate; parathyroid hormone; calcitonin; receptor activator of nuclear factor κB; sclerostin; stem cell 1. Introduction At the Consensus Development Conference in 1993, osteoporosis was defined as a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture [1]. The World Health Organization Study Group has proposed general criteria for the diagnosis of osteoporosis based on dual-energy X-ray absorptiometry, which is considered the standard tool for the evaluation of osteoporosis. According to the criteria, osteoporosis is diagnosed when the bone mineral density (BMD) is 2.5 or more standard deviations below the young-adult mean [2,3]. The incidence of osteoporosis increases with aging. In addition, the population aged 60 years or older has been continuously growing in many countries [4]. More than 75 million people have osteoporosis in Europe, Japan, and the USA alone [2]. Worldwide, it is estimated that 9 million people suffer from osteoporotic fractures each year [5]. Therefore, treatments for osteoporosis with various medicines have been receiving increasing attention globally. Osteoporosis is caused by an imbalance in bone remodeling, which is an ongoing process in which mature bone tissue is removed by osteoclasts (bone resorption) and new bone tissue is formed by osteoblasts (bone formation). Excessive bone resorption or inadequate new bone formation during bone remodeling can result in osteoporosis [6]. To maintain bone homeostasis, osteoblast and osteoclast functions are coordinated by a wide variety of molecules (Figure1). Int. J. Mol. Sci. 2019, 20, 2557; doi:10.3390/ijms20102557 www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2019, 20, 2557 2 of 24 Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 2 of 24 Figure 1. SchematicSchematic diagram diagram of ofbone bone ho homeostasismeostasis and and a summary a summary of the of theaction action mechanism mechanism of the of agentsthe agents for osteoporosis. for osteoporosis. BP, bisphosphonate; BP, bisphosphonate; DKK, dickkopf; DKK, dickkopf; M-CSF, M-CSF,monocyte/macrophage monocyte/macrophage colony- stimulatingcolony-stimulating factor; PTH, factor; parathyroid PTH, parathyroid hormone; hormone; normal normalarrows arrowswith “+” with mean “+ ”positive mean positive effect; dotted effect; arrowsdotted arrowswith “− with” mean “ ”negative mean negative effect. This effect. figure This is figure copyright is copyright free. free. − Osteoblasts originate originate from from mesenchymal mesenchymal stem stem cells cells (MSCs). (MSCs). Runt-related Runt-related transcription transcription factor factor 2 (Runx2),2 (Runx2), also also known known as core-binding as core-binding factor factor subunit subunit alpha-1, alpha-1, is a key istranscription a key transcription factor for osteoblast factor for differentiationosteoblast diff erentiationfrom MSCs from and MSCspre-osteoblasts. and pre-osteoblasts. Runx2 expression Runx2 is expression the first requisite is the first step requisite in the determinationstep in the determination of osteoblast of osteoblastcommitment, commitment, followed by followed expression by expression of Sp7 and of Tcf7, Sp7 andwhich Tcf7, are which also essentialare also essentialfor osteoblastic for osteoblastic differentiation differentiation [7]. Runx2 [7]. is Runx2regulated is regulated by multiple by multiplesignals, such signals, as bone such morphogeneticas bone morphogenetic proteins proteins (BMPs) (BMPs) and Wnt/ and Wntβ-catenin./β-catenin. As for As forBMP BMP signaling, signaling, SMAD1/5/8 SMAD1/5/8 are phosphorylated particularly by BMP2 and BMP4, BMP4, and and finally, finally, stimulate osteoblast differentiation differentiation by activating Runx2. Regarding Regarding Wnt/ Wnt/β-catenin-catenin signaling, signaling, Wnt Wnt proteins proteins (particularly (particularly Wnt3a Wnt3a and and Wnt10b) Wnt10b) bind toto Frizzled Frizzled and and lipoprotein lipoprotein receptor-related receptor-relat proteined protein (LRP)-5 (LRP)-5/6/6 receptors, receptors, and consequently and consequently increase increaseRunx2 levels Runx2 through levels eitherthroughβ-catenin either β stabilization-catenin stabilization or protein or kinase protein Cδ kinase[8,9]. SclerostinCδ [8,9]. Sclerostin and dickkopf and (DKK)-1dickkopf inhibit(DKK)-1 the inhibit Wnt/β -cateninthe Wnt/ pathwayβ-catenin through pathway the through LRP-5/6 the receptor, LRP-5/6 thus receptor, leading thus to a decreaseleading to in aRunx2 decrease expression. in Runx2 expression. Osteoclasts differentiate differentiate from hematopoietic st stemem cells through monocytemonocyte/macrophage/macrophage lineage upon stimulation with monocytemonocyte/macrophage/macrophage colony-s colony-stimulatingtimulating factor factor and ac activationtivation of receptor activator ofof nuclearnuclear factorfactorκ κBB (RANK) (RANK) by by its its ligand ligand (RANKL) (RANKL) [10 [1].0]. RANKL RANKL secreted secreted by osteoblastsby osteoblasts and andosteocytes osteocytes binds binds to RANK to RANK on osteoclast on osteoclast precursor precursor cells, which cells, eventually which eventually differentiate differentiate into osteoclasts. into osteoclasts.Osteoprotegerin Osteoprotegerin (OPG), which (OPG), is also which produced is also by produced cells in the by osteoblast cells in the lineage, osteoblast is a soluble lineage, decoy is a solublereceptor decoy of RANKL receptor that of preventsRANKL that binding prevents of RANKL binding to of RANK RANKL [11 ].to RANK The RANKL-RANK-OPG [11]. The RANKL- RANK-OPGinteraction plays interaction an essential plays role an inessential bone homeostasis role in bone through homeostasis osteoclast through regulation osteoclast [12]. regulation [12]. Osteocytes, which are completely embedded in the bone matrix, descend from MSCs through osteoblastOsteocytes, differentiation which are and completely orchestrate embedded bone remodeling in the bone by regulatingmatrix, descend osteoblasts from andMSCs osteoclasts. through osteoblastEspecially, differentiation they exclusively and secrete orchestrate sclerostin bone [13 remo]. deling by regulating osteoblasts and osteoclasts. Especially,Treatments they forexclusivel osteoporosisy secrete are sclerostin divided into [13]. several groups, including therapies based on essential nutrients,Treatments anti-resorption for osteoporosis drugs, anabolic are divided drugs, into and combinationsseveral groups, of these.including Major therapies essential based nutrients on essentialfor the treatment nutrients, of anti-resorption osteoporosis are drugs, calcium, anabolic vitamin drugs, D, and combinations vitamin K2, all of of these. which Major are involvedessential nutrients for the treatment of osteoporosis are calcium, vitamin D, and vitamin K2, all of which are involved in bone metabolism. Anti-resorptive drugs, which suppress bone resorption, include Int. J. Mol. Sci. 2019, 20, 2557 3 of 24 in bone metabolism. Anti-resorptive drugs, which suppress bone resorption, include calcitonin, estrogen and selective estrogen receptor modulators (SERMs), bisphosphonates (BPs), and anti-RANKL antibody. Anabolic drugs, which enhance bone formation, include parathyroid hormone (PTH) and sclerostin inhibitors. Additionally, stem cell therapies for osteoporosis have been receiving increased attention in recent years. These therapies are helpful for the treatment of osteoporosis as evidenced by numerous clinical trials. However, nearly all these therapies have side effects because of the long-term drug administration for osteoporosis treatment. In this literature review, we summarize the mechanisms of action of current and anticipated
Recommended publications
  • Efficacy and Safety of Elcatonin in Postmenopausal Women with Osteoporosis: a Systematic Review with Network Meta-Analysis of Randomized Clinical Trials
    Osteoporosis International (2019) 30:1723–1732 https://doi.org/10.1007/s00198-019-04997-6 REVIEW Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials W.-C. Chen1,2 & E.-Y. Lin3 & Y.-N. Kang1,4 Received: 20 November 2018 /Accepted: 21 April 2019 /Published online: 1 May 2019 # International Osteoporosis Foundation and National Osteoporosis Foundation 2019 Abstract Summary The present systematic review aimed to evaluate bone mineral density (BMD) change and complication rates of elcatonin on treating postmenopausal osteoporosis. The result confirmed efficacy of elcatonin and safety in combination thera- pies of elcatonin (C-E). Introduction Postmenopausal osteoporosis is an important issue in global aging trends. One treatment of osteoporosis is elcatonin, a kind of calcitonin. However, it has been challenged for long time because of safety. Many trials investigated on this topic, but they were designed differently. Those designs can be categorized in monotherapy of elcatonin (M-E) and C-E. Unfortunately, no synthesized evidence dealt this topic. Methods This study systematically identified target trials from six important databases and only included randomized controlled trial for synthesis. Two investigators assessed quality of eligible trials using the Cochrane Risk of Bias Tool, and they indepen- dently extracted data. Network meta-analysis performed Peto odds ratio (POR, used for dealing with zero cell) or weighted mean difference (WMD, for continuous data) with 95% confidence intervals (CI) and consistency H. Results Sixteen trials recruiting 2754 women with postmenopausal osteoporosis were included in our study. Elcatonin therapies and non-elcatonin medications had comparable fracture rates and bone mineral density change.
    [Show full text]
  • 1 Advances in Therapeutic Peptides Targeting G Protein-Coupled
    Advances in therapeutic peptides targeting G protein-coupled receptors Anthony P. Davenport1Ϯ Conor C.G. Scully2Ϯ, Chris de Graaf2, Alastair J. H. Brown2 and Janet J. Maguire1 1Experimental Medicine and Immunotherapeutics, Addenbrooke’s Hospital, University of Cambridge, CB2 0QQ, UK 2Sosei Heptares, Granta Park, Cambridge, CB21 6DG, UK. Ϯ Contributed equally Correspondence to Anthony P. Davenport email: [email protected] Abstract Dysregulation of peptide-activated pathways causes a range of diseases, fostering the discovery and clinical development of peptide drugs. Many endogenous peptides activate G protein-coupled receptors (GPCRs) — nearly fifty GPCR peptide drugs have been approved to date, most of them for metabolic disease or oncology, and more than 10 potentially first- in-class peptide therapeutics are in the pipeline. The majority of existing peptide therapeutics are agonists, which reflects the currently dominant strategy of modifying the endogenous peptide sequence of ligands for peptide-binding GPCRs. Increasingly, novel strategies are being employed to develop both agonists and antagonists, and both to introduce chemical novelty and improve drug-like properties. Pharmacodynamic improvements are evolving to bias ligands to activate specific downstream signalling pathways in order to optimise efficacy and reduce side effects. In pharmacokinetics, modifications that increase plasma-half life have been revolutionary. Here, we discuss the current status of peptide drugs targeting GPCRs, with a focus on evolving strategies to improve pharmacokinetic and pharmacodynamic properties. Introduction G protein-coupled receptors (GPCRs) mediate a wide range of signalling processes and are targeted by one third of drugs in clinical use1. Although most GPCR-targeting therapeutics are small molecules2, the endogenous ligands for many GPCRs are peptides (comprising 50 or fewer amino acids), which suggests that this class of molecule could be therapeutically useful.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • Elcatonin (Rinn) Sensitivity Reactions, Including Anaphylaxis, Have Pression of the Airway Or Vulnerable Neurological Structures
    Bone Morphogenetic Proteins/Calcitonins 1093 ports of swelling of neck and throat tissue, with resultant com- Elcatonin (rINN) sensitivity reactions, including anaphylaxis, have pression of the airway or vulnerable neurological structures. [Aminosuberic Acid 1,7]-eel Calcitonin; [Asu1,7]-E-CT; Carbocal- occurred. Complications were often life-threatening, and had required res- piratory support and/or tracheotomy in some cases. The use of citonin; Elcatonina; Elcatonine; Elcatoninum. 1-Butyric acid-7-(L- Calcitonin has inhibited lactation in animals. alternative treatments or enrollment in approved clinical studies 2-aminobutyric acid)-26-L-aspartic acid-27-L-valine-29-L-alanine- Nausea and vomiting may be reduced by giving doses 1 calcitonin (salmon). was recommended when treating cervical spine problems. at bedtime or by giving an antiemetic beforehand. 1. FDA. FDA Public Health Notification: Life-threatening compli- Элькатонин cations associated with recombinant human bone morphogenetic Calcitonin (pork) may contain trace amounts of thyroid C148H244N42O47 = 3363.8. protein in cervical spine fusion. Available at: http:// CAS — 60731-46-6. hormones, but clinical effects are unlikely in most pa- www.fda.gov/cdrh/safety/070108-rhbmp.html (accessed 17/07/08) ATC — H05BA04. tients. ATC Vet — QH05BA04. Preparations Antibody formation. Long-term treatment with heterologous Description. Elcatonin is a synthetic analogue of eel calcitonin. calcitonins may lead to the formation of neutralising antibodies. Proprietary Preparations (details are given in Part 3) Pharmacopoeias. In Jpn. This appears to be common in patients given calcitonin (pork) or, Belg.: InductOs; Cz.: InductOs; Osigraft; Denm.: InductOs; Osigraft; Fin.: to a lesser extent, calcitonin (salmon). Calcitonin (human) is less InductOs; Gr.: InductOs; Osigraft; Irl.: InductOs; Ital.: Osigraft; Neth.: Os- 1 igraft; Norw.: InductOs; Port.: Osigraft; Spain: InductOs; Osigraft; Swed.: Incompatibility.
    [Show full text]
  • Raloxifene Or Calcitonin
    Appendices Table of Contents Appendix A. Search Strategy ................................................................................................... A-1 Appendix B. Risk of Bias Assessment Decision Aid .............................................................. B-1 Appendix C. Included References Risk of Bias Assessment ................................................. C-1 Appendix D. Evidence Tables .................................................................................................. D-1 Table D1. Characteristics of observational studies with low or medium risk of bias ............ D-1 Table D2. Characteristics of RCTs and CCTs with low or medium risk of bias .................... D-6 Table D3. Key Questions 1 & 2 Evidence Overview ........................................................... D-15 Table D4. Key Questions 3 & 4 Evidence Overview ........................................................... D-28 Table D5. Key Questions 5 & 6 Evidence Overview ........................................................... D-45 Table D6. Key Questions 7 & 8 Evidence Overview ........................................................... D-50 Table D7. Characteristics of eligible studies with high risk of bias ..................................... D-52 Strength of Evidence Tables ..................................................................................................... 57 Alendronate ....................................................................................................................... D-57 Table D8.
    [Show full text]
  • Use of Serotonin Reuptake Inhibitors and Risk of Subsequent Bone Loss In
    www.nature.com/scientificreports OPEN Use of serotonin reuptake inhibitors and risk of subsequent bone loss in a nationwide population‑based cohort study Sunyoung Kang1,6, Minkyung Han2,6, Chun Il Park3, Inkyung Jung4, Eun Hwa Kim2, Young Jun Boo1, Jee In Kang1,5* & Se Joo Kim1,5* This study examined whether the use of SRIs is associated with an increased risk of bone loss using a nested case–control design with a nationwide population–based cohort in Korea. Using the Korean National Health Screening Cohort, subjects newly diagnosed with osteoporosis or osteopenia (n = 55,799) were matched with controls (n = 278,995) at a ratio of 1:5. We stratifed the participants by their time‑dependent use of SRIs and sex and controlled for various confounders, including lifestyle habits, laboratory data, and comorbidities. Conditional logistic regression showed that both recent and former users of SRIs had an increased risk of subsequent bone loss compared with non‑users: men [recent users: odds ratio (OR) 1.35, 95% confdential interval (CI) 1.20, 1.53; former‑users: OR 1.10, 95% CI 1.01, 1.20]; women (recent users: OR 1.38, 95% CI 1.28–1.48; former‑users: OR 1.07, 95% CI 1.02, 1.21). The use of SRIs was associated with an increased risk of bone loss in both men and women. In particular, the association was stronger in recent users. These fndings provide population‑ level evidence for the risk of bone loss associated with SRI exposure and highlight the importance of monitoring the bone health of SRI users.
    [Show full text]
  • Vertebroplasty and Kyphoplasty As Treatment for Osteoporotic Vertebral Fractures
    ISSN 1889-836X Volume 2 Number 2 July 2010 Revista de Osteoporosis y Metabolismo Mineral EDITORIALS Bone Pathology of Gaucher's Disease 5 López-Herce Cid JA The paradox of vitamin D deficiency in sunny regions, in young people, or in osteoporotic 7 patients treated with vitamin D, could be explained by common genetic variation. Have we found the Rosetta Stone to this apparent contradiction? Quesada Gómez JM ORIGINAL ARTICLES Factors related to vitamin D deficiency in medical students in Gran Canaria 11 Groba Marco MV, Mirallave Pescador A, González Rodríguez E, García Santana S, González Padilla E, Saavedra Santana P et al Effect of zoledronic acid on the markers for bone remodelling in Paget’s disease 21 Díaz Curiel M, Serrano Morales R, De la Piedra Gordo C, Moro Álvarez MJ, Andrade Poveda M Vertebroplasty and kyphoplasty as a treatment for osteoporotic fractures 27 Pérez-Núñez MI, Riancho Moral JA REVIEWS Importance of the type of formulation of the preparations of calcium and vitamin D in the prevention 35 and treatment of osteoporosis García Quetglas E, Urdaneta Abate M, Sádaba Díaz de Rada B, Landecho Acha M, Lucena Ramírez F, Azanza Perea JR Cardiovascular disease, type 2 diabetes and osteoporosis 47 Reyes García R, Rozas Moreno P, Muñoz Torres M Determining the principal metabolites of vitamin D in the blood through on-line solid phase 55 extraction with liquid chromatography-mass spectrometry in tandem Mata-Granados JM, Ferreiro-Verab C, Luque de Castro MD, Quesada Gómez JM SPECIAL DOCUMENTS Current perspectives on the role of
    [Show full text]
  • Pharmacological Study of Teriparatide on Ovariectomy-Induced Hyperalgesia in Rats
    Title Pharmacological study of teriparatide on ovariectomy-induced hyperalgesia in rats Author(s) 田中, 智哉 Citation 北海道大学. 博士(歯学) 甲第13876号 Issue Date 2020-03-25 DOI 10.14943/doctoral.k13876 Doc URL http://hdl.handle.net/2115/78480 Type theses (doctoral) File Information Tomoya_Tanaka.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP 博 士 論 文 Pharmacological study of teriparatide on ovariectomy-induced hyperalgesia in rats (卵巣摘除ラットモデルを用いた骨粗鬆性痛覚過 敏に対するテリパラチドの薬理作用の解明) 令和 2 年 3 月申請 北海道大学 大学院歯学研究科口腔医学専攻 田 中 智 哉 目次 Introduction .................................................................................................................. 3 Materials and methods ................................................................................................ 4 Experimental animals ....................................................................................................................4 Experimental design ......................................................................................................................4 Pain-related behavioral test ...........................................................................................................5 Plantar test ................................................................................................................................. 5 von Frey test ..............................................................................................................................6 Skeletal analyses ...........................................................................................................................6
    [Show full text]
  • Supplement Ii to the Japanese Pharmacopoeia Seventeenth Edition
    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION O‹cial from June 28, 2019 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. Printed in Japan The Ministry of Health, Labour and Welfare Ministerial Notification No. 49 Pursuant to Paragraph 1, Article 41 of Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Act No. 145, 1960), this notification stated that a part of the Japanese Pharmacopoeia was revised as follows*. NEMOTO Takumi The Minister of Health, Labour and Welfare June 28, 2019 A part of the Japanese Pharmacopoeia (Ministerial Notification No. 64, 2016) was revised as follows*. (The text referred to by the term ``as follows'' are omitted here. All of the revised Japanese Pharmacopoeia in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'' in Supplement 2) are made available for public exhibition at the Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmen- tal Health Bureau, Ministry of Health, Labour and Welfare, at each Regional Bureau of Health and Welfare, and at each Prefectural Office in Japan). Supplementary Provisions (Effective Date) Article 1 This Notification is applied from June 28, 2019. (Transitional measures) Article 2 In the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as ``previous Pharmacopoeia'') [limited to those listed in new Pharmacopoeia] and drugs which have been approved as of June 28, 2019 as prescribed under Paragraph 1, Article 14 of Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Orphan Drug Designation List
    Orphan Drug Designations and Approvals List as of 06‐01‐2016 Governs July 1, 2016 ‐ September 30, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 (-)-(3aR,4S,7aR)-4-Hydroxy-4- m-tolylethynyl-octahydro- Novartis indole-1-carboxylic acid Pharmaceuticals methyl ester n/a 10/12/2011 Treatment of Fragile X syndrome Corp. 2 (1-methyl-2-nitro-1H- imidazole-5-yl)methyl N,N'- bis(2-broethyl) diamidophosphate n/a 6/5/2013 Treatment of pancreatic cancer EMD Serono 3 (1-methyl-2-nitro-1H- imidazole-5-yl)methyl N,N'- bis(2-bromoethyl) Threshold diamidophosphate n/a 3/9/2012 Treatment of soft tissue sarcoma Pharmaceuticals, Inc. 4 (1OR)-7-amino-12-fluoro- 2,10,16-trimethyl-15 oxo- 10,15,16,17-tetrahydro-2H-8,4- Treatment of anaplastic (metheno)pyrazolo[4,3- lymphoma kinase (ALK)-positive h][2,5,11]benzoxadiazacyclote or ROS1-positive non-small cell tradecine-3-carbonitrile n/a 6/23/2015 lung cancer Pfizer, Inc. 5 (1R,3R,4R,5S)-3-O-[2-O- Treatment of vaso-occlusive benzoyl-3-O-(sodium(2S)-3- crisis in patients with sickle cell cyclohexyl-propanoate- n/a 2/17/2009 disease. Pfizer, Inc. 6 (1S)-1-(9-deazahypoxanthin-9- yl)-1,4-dideoxy-1,4-imino-D- Treatment of T-cell non- Mundipharma ribitol-hydrochloride n/a 1/29/2004 Hodgkin's lymphoma Research Limited 7 (1S)-1-(9-deazahypoxanthin-9- yl)-1,4-dideoxy-1,4-imino-D- Treatment of acute Mundipharma ribitol-hydrochloride n/a 8/13/2004 lymphoblastic leukemia Research Limited Page 1 of 364 Orphan Drug Designations and Approvals List as of 06‐01‐2016 Governs July 1, 2016 ‐ September 30, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 8 Treatment of chronic lymphocytic leukemia and related leukemias to include (1S)-1-(9-deazahypoxanthin-9- prolymphocytic leukemia, adult T- yl)-1,4-dideoxy-1,4-imino-D- cell leukemia, and hairy cell Mundipharma ribitol-hydrochloride n/a 8/10/2004 leukemia Research Ltd.
    [Show full text]